NOVOLOG MIX 70/30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLOG MIX 70/30 (NOVOLOG MIX 70/30).
Biphasic insulin analog combining rapid-acting insulin aspart and intermediate-acting protamine-crystallized insulin aspart, which lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production.
| Metabolism | Insulin aspart is primarily metabolized by insulin-degrading enzyme (IDE) and undergoes hepatic and renal clearance. |
| Excretion | Renal: 30-80% of dose excreted unchanged in urine for insulin aspart; for protamine-crystallized component, metabolism and renal elimination also occur. Biliary/fecal: Minor. |
| Half-life | Insulin aspart (free component): ~1-2 hours; protamine-crystallized component: ~8-10 hours. Clinical context: Duration of action up to 24 hours due to the intermediate-acting component. |
| Protein binding | <5% bound to plasma proteins (insulin aspart). |
| Volume of Distribution | ~0.26 L/kg for insulin aspart. Clinical meaning: Reflects distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: 60-80% for insulin aspart component. |
| Onset of Action | Subcutaneous: 10-20 minutes. |
| Duration of Action | Subcutaneous: Up to 24 hours. Clinical notes: Biphasic profile with rapid onset from aspart and prolonged effect from protamine-crystallized aspart. |
Subcutaneous injection only. Typical total daily insulin dose ranges from 0.5 to 1.0 units/kg/day divided into two or three injections. Administer twice daily, with each dose given within 15 minutes before meals. Dose individualization based on glycemic targets and previous insulin regimen is required.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 45 mL/min/1.73m², reduced insulin clearance may increase risk of hypoglycemia; initiate with lower starting doses (e.g., 0.3-0.5 units/kg/day) and titrate cautiously. No specific dose adjustment guidelines; clinical monitoring recommended. |
| Liver impairment | In hepatic impairment (Child-Pugh A, B, or C), decreased gluconeogenesis may increase hypoglycemia risk. Initiate with conservative doses (e.g., 50% of standard starting dose) and titrate slowly based on glycemic response and frequent blood glucose monitoring. |
| Pediatric use | For children ≥2 years, initial total daily insulin dose 0.5-1.0 units/kg/day administered subcutaneously in two divided doses (usually before breakfast and before evening meal). Adjust based on premeal and nocturnal glucose levels. For adolescents, doses may approach 1.0-1.2 units/kg/day. Individualize based on glycemic targets and developmental stage. |
| Geriatric use |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLOG MIX 70/30 (NOVOLOG MIX 70/30).
| Breastfeeding | Insulin aspart is a large protein that is unlikely to pass into breast milk in significant amounts. M/P ratio not established. Considered compatible with breastfeeding; may require adjustment of maternal insulin dose. |
| Teratogenic Risk | Insulin aspart does not cross the placenta in significant amounts. There is no evidence of teratogenicity from insulin analogs. Uncontrolled maternal diabetes, however, increases risks of congenital malformations (first trimester), macrosomia, neonatal hypoglycemia, and respiratory distress (third trimester). |
■ FDA Black Box Warning
Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia; these changes should be made cautiously under close medical supervision.
| Common Effects | Eye irritation Burning eyes |
| Serious Effects |
["Hypoglycemia","Hypersensitivity to insulin aspart or any excipients"]
| Precautions | ["Hypoglycemia is the most common adverse effect","Never mix with other insulins","Accidental mix-ups between insulin products can occur","May cause hypokalemia","Fluid retention and heart failure when used with thiazolidinediones"] |
Loading safety data…
| In elderly patients (≥65 years), lower initial doses (e.g., 0.3-0.5 units/kg/day) due to increased risk of hypoglycemia and potential renal impairment. Titrate cautiously with less aggressive glycemic goals (e.g., HbA1c <7.5-8.0%) to avoid adverse events. Monitor renal function and cognitive status. |
| Fetal Monitoring |
| Monitor blood glucose and HbA1c throughout pregnancy. Fetal surveillance: ultrasound for growth and anatomy, nonstress tests, biophysical profile. Monitor for maternal hypoglycemia and diabetic ketoacidosis. |
| Fertility Effects | No direct effects on fertility. Poor glycemic control can impair fertility in both males and females. Optimizing glycemic control prior to conception is recommended. |